FDA Approved: ALYMSYS — Original Application (Amneal Pharmaceuticals LLC)

View source ↗

Summary

FDA approves ALYMSYS as a biosimilar to bevacizumab (bevaczizumab-maly) from Amneal Pharmaceuticals LLC under an original Biologics License Application.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Cancer
• Colorectal Cancer
• Fallopian Tube Cancer
• Glioblastoma
• Non-small Cell Lung Cancer
• Ovarian Cancer
• Peritoneal Cancer
• Renal Cell Carcinoma

Drugs mentioned

• Alymsys (bevacizumab)

Snippet

ORIG AP for ALYMSYS (BEVACIZUMAB-MALY)